AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMGN is a good long-term buy for a beginner with $50,000-$100,000 available, and it is reasonable to buy now rather than wait. The stock is trading in an overall bullish technical structure, analyst sentiment is mostly constructive with several Overweight/Buy views, and the current price is still below the higher price targets from the bullish analysts. The lack of a bearish proprietary trading signal and the positive long-term business profile support accumulation at current levels.
AMGN is in a constructive uptrend. MACD remains positive at 1.42, the RSI_6 is neutral at 56.47, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Price at 335.07 is just below resistance at 341.46 (R1) and above pivot support at 332.74, which suggests the stock is holding trend support rather than breaking down. The short-term pattern data also points to modest upside probability over the next day, week, and month.
["Analysts continue to see upside from Amgen's rare disease portfolio, especially Uplizna.", "Piper Sandler sees top-line upside into 2026 and 2027.", "Strong Phase III data for the subcutaneous formulation of Tepezza could support another growth driver.", "Q1 results were described by analysts as in line to slightly better, with guidance improving modestly.", "The stock has already shown strong 1-year performance, reflecting durable investor confidence."]
["Some analysts expect sales growth to slow in 2026 and 2027.", "Several firms have neutral or cautious ratings, including Hold, Equal Weight, and Underperform.", "Mature products face weakness, loss of exclusivity, and pricing pressure.", "Congress trading activity is net negative with more sales than purchases.", "The stock has recently moved up enough that some upside is viewed as more limited by certain brokers."]
Latest quarter: Q1 2026. The financial read-through was generally solid. Analysts said revenue was in line with expectations and earnings beat estimates, helped by lower SG&A costs and taxes. Guidance was raised modestly, and growth drivers remained intact. The quarter is described as seasonally weak, but the business still appears to be delivering stable operating performance with support from innovative products offsetting mature-product softness.
Analyst sentiment is mixed but leaning constructive. Recent changes include Piper Sandler maintaining Overweight and raising the target to $427, Freedom Broker upgrading to Buy, and several firms keeping Hold/Neutral views. There is also a bearish Underperform from BofA and a Hold downgrade from Erste Group, reflecting concerns about slower growth and limited medium-term upside. Overall, Wall Street pros appear split: the bull case is driven by rare disease growth and pipeline catalysts, while the bear case focuses on valuation, mature-product pressure, and slower growth ahead.
